Financial firms are acquiring music catalogs not as creative assets, but as a form of real estate. They act as 'musical landlords,' collecting passive income or 'rent' via royalties every time a song is streamed. This transforms popular music into a stable, revenue-generating asset class for investors.

Altius thrives by providing capital to mining projects during industry downturns when financing is expensive or unavailable. They then benefit as the cycle turns, projects get developed with others' capital, and commodity prices rise, amplifying their royalty returns.

Since one cannot own sun or wind, Altius created novel intellectual property to structure royalty-like contractual interests in renewable projects. They provide early-stage capital to developers in exchange for a long-term revenue share from future power generation, effectively creating a new asset class.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

Altius doesn't just buy royalties; its geology team proactively identifies and stakes mineral claims. It then structures a royalty into the claim and sells the project to an operator, retaining the royalty and often an equity stake. This creates proprietary deal flow and massive returns.

The royalty model provides immense embedded optionality. Once the royalty is established, the holder benefits from any upside—like project expansions or new efficiencies—without having to fund the associated capital expenditures. The mine operator bears all future costs and risks for this growth.

Companies like Natural Resource Partners (NRP) own mineral rights and collect royalties per ton mined, avoiding the high operating expenses and capital expenditures of producers. This model, with 90% free cash flow margins and long-term leases, creates a durable, asymmetric bet on a commodity.

Candle Therapeutics secured $100M not through equity, but by selling a percentage of future US sales of its Phase III cancer therapy. This non-dilutive royalty financing provides capital for a product launch without giving up ownership, a strategic option for companies nearing FDA approval.

ReSeed's partnership model isn't a traditional equity stake. They take a 10% top-line revenue share from the operator's business in exchange for seed capital and, more importantly, the exclusive right (but not obligation) to fund up to 100% of the equity for future deals.